Th180 - RICORS-TERAV: The Spanish Model for Collaborative Research in Academic Cell Immunotherapy, for Transfering Knowledge to the Clinic or the Benefit of Patient

Felipe Prosper – COORDINATOR OF IMMUNOTHERAPY AND CAR T CELL PROGRAM AT TERAV, Cell Therapy Unit - RICORS-TERAV, UNAV - RICORS-TERAV; Agustin Zapata – COORDINATOR OF TERAV NETWORK, Biologia Celular, UCM - RICORS-TERAV; Jose Moraleda – COORDINATOR OF TERAV NETWORK, Hematology - RICORS-TERAV, IMIB-Arrixaca - RICORS-TERAV; On behalf of RICORS-TERAV – TERAV Network, RICORS - TERAV, ISCIII - RICORS-TERAV

Abstract Text: RICORS-TERAV is a public network of 32 research groups and more than 350 academic (basic and clinical) researchers in cell therapy promoted by the Instituto de Salut Carlos III of the Government of Spain to promote collaborative research in Advanced Therapies and the clinical translation of this knowledge for the benefit of patients (from 2022 to 2024). With 4 coordinated programs, this summary presents the main aspects related to program "IMMUNOTHERAPY AND CAR T CELL PROGRAM". This program 2 is also named "Immunocell" and it is mainly focused in antitumoral Immunotherapy, specially CAR proposals, for obtaining therapeutic products that could be used in the Spanish public health system. It is structurated in 3 work packages (aims): WP1: Identification, development and validation of new engineered IT products with increased efficacy and safety (basic and preclinical research). WP2: Improvemente of production strategies for delivering better ATMPs products (translational research and innovations) & WP3: Aplication of innovative clinical engineered IT programs for the treatment of solid and hematological tumors (Clinical production, RWD analysis and applied research). In these early years, several Academic CAR-T developments are already under clinical trials. The authorization for use (under the so-called "hospital exemption" rule) is the first option for translating these products, a concept that in many countries it is being named the "Spanish Model".